​On October 12, 2020, Curon Biopharma, a Shanghai-based clinical-stage biopharmaceutical company, acquired exclusive rights to Tenalisib from Rhizen Pharma of Switzerland for exploitation in greater China. Tenalisib is a next-generation dual PI3K δ/γ inhibitor, which is in Phase 2 clinical development for hematological malignancies. Tenalisib has been granted U.S. FDA Fast Track Designations for treatment of relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma, in addition to Orphan-Drug Designations for treatment of peripheral and cutaneous T-cell lymphoma. Rhizen Pharma will be eligible to receive upfront and milestone payments worth up to $149.5 million, as well as tiered royalties on annual net sales of Tenalisib.

In 2018, Curon raised $150 million in a Series A financing led by 6 Dimensions Capital, Boyu Capital and Temasek. Since its initial financing, Curon has been committed to developing next-generation cancer immunotherapies for patients.

The Wilson Sonsini team that advised Curon in licensing matters related to this transaction includes Alexander Key, Karen Wong, and Kexi Wang. The Wilson Sonsini team led by Karen Wong and Richard Wang​ also advised Curon on IP matters in connection with its Series A financing.

For more information, please see the latest press coverage.